ALTANA AG

ALTANA is a privately held German specialty chemicals group that sells low-volume, high-functionality ingredients and formulated materials to industrial customers. Its four divisions are BYK (additives and measuring instruments), ECKART (metallic effect pigments), ELANTAS (electrical insulation materials) and ACTEGA (coatings, inks and sealants for packaging). Each holds a leading position in a narrow niche where the product is a small share of the customer's cost but decisive for performance. The group generated sales of €3,080.6 million and EBITDA of €523.0 million (17.0% margin) in FY2025, spends about 7% of sales on R&D, and ended 2025 with net financial assets of €207.0 million and a 70% equity ratio. Single-family ownership through SKion allows a long investment horizon: stable capex of 5–6% of sales, bolt-on acquisitions (Von Roll 2023, Silberline 2024, perisens 2026) and a decentralized operating model. The main open issue is margin: EBITDA margin has been below the 18–20% target range since 2022.

Company's own description. CR2025 describes the ALTANA Group as "a global supplier of specialized chemical products and related services for different branches of industry and application fields". The standard boilerplate in its press releases calls ALTANA "a global leader in true specialty chemicals" offering solutions for coating manufacturers, paint and plastics processors, the printing and packaging industries, the cosmetics sector, and the electrical and electronics industry. The stated product range covers additives, specialty coatings and adhesives, effect pigments, sealants and compounds, impregnating resins and varnishes, and testing and measuring instruments.

Mission (CR2025). The company states that it provides innovative solutions based on integrated chemical, formulation and application expertise that make products of daily life better and more sustainable, and that it creates value for customers, employees, its shareholder and society.

Independent characterization. ALTANA is a portfolio of four B2B niche franchises with a common economic logic. The products are performance-critical but used in small quantities, so customers buy on technical fit and service rather than on price per kilogram. That supports high gross margins, a large application-laboratory network close to customers, and R&D intensity roughly twice the chemical industry average (company claim, PR FY2025). The model is formulation- and application-driven rather than asset-heavy: capex runs at 5–6% of sales and the company says it consumes significantly less energy than the industry average (PR H1 2026).

Revenue model. Essentially 100% product sales. There is no disclosed subscription or licensing revenue. The exceptions are small: BYK-Gardner instruments carry service and software elements, and ACTEGA's Signite and ECOLEAF decoration technologies combine equipment with consumables. Revenue split between products and services is not publicly disclosed.

Value chain position. ALTANA sits between basic and intermediate chemical producers (resins, solvents, silicones, aluminium, copper, zinc, mica) and formulators or converters. Raw materials and packaging are the largest cost item, at 42.0% of sales in FY2025 (43.3% in FY2024) per CR2025. Personnel costs were 24.1% of sales (23.5% in FY2024).

Customer types and end-markets.

Demand characteristics (CR2025). Demand is seasonal (Chinese New Year, summer holidays, year-end), cyclical through customer inventory behaviour, and sensitive to raw-material price expectations. Long-term demand is shaped by megatrends, regional growth and technology change.

Stated strategy (CR2025). ALTANA's strategy is "consistently geared toward sustainable profitable growth in future-oriented specialty chemicals markets", with the top financial priority "to sustainably increase the company's value". Profitable growth rests on four aspects: operational expansion in existing markets and adjacent segments; innovation as the core of problem-solving expertise; alignment of the business with sustainability, including defossilization and circular materials; and acquisitions that add value chain segments, markets or technologies.

Medium- and long-term targets (CR2025)

Initiatives announced in the last 24 months

No cost-reduction programme with a quantified target has been announced. ALTANA does not hold investor days.

Product-group descriptions are from CR2025. Pricing across all divisions is negotiated B2B pricing per kilogram, per unit or per system; no list prices are published.

BYK — Additives & Instruments

A wind-turbine rotor-blade additive, described as the first certified additive of its kind, was presented in 2021 (PR FY2021).

ECKART — Effect Pigments

CR2025 notes that ECKART's aluminium granules have an aluminium content of 99.7–99.8% with guaranteed purity of at least 99.5%.

ELANTAS — Electrical Insulation

In 2021 ELANTAS filed a patent application for a dye-based process to detect wear in electric motors (PR FY2021).

ACTEGA — Coatings & Sealants

CR2025 states that ACTEGA sold more than 15,000 unique products in 2025, that more than 80% of its innovation pipeline targets sustainable solutions, and that over 25% of revenue comes from new products.

Income statement

Sources: CR2021, CR2023, CR2024, CR2025, PR FY2021, PR FY2023. Sales CAGR FY2021–FY2025 is 3.7% (derived). Gross profit is not reported in the sources reviewed. EPS and dividends per share are not applicable in a meaningful sense for a wholly owned company and are not published in the Corporate Report.

Commentary. FY2021 was a post-pandemic demand peak with an 18.1% EBITDA margin inside the target range. FY2022 delivered record sales on price increases, but margin fell three points as material, logistics and energy costs outran pricing. FY2023 was the trough: destocking along the value chain cut sales 9% and EBITDA 15%, and net income more than halved to €110.2 million, burdened by acquisition costs and equity-method losses (the Landa associate recorded a net loss of roughly €159 million at 100% in 2023 per the Consolidated Financial Statements 2023). FY2024 recovered on volume and acquisitions (sales +16%, EBITDA +27%). FY2025 shows margin recovery to 17.0% on a 3% lower nominal top line. Quality of earnings needs care: CR2025 states that other operating income included €45.4 million of insurance reimbursements for property damage from prior years and resulting business interruptions, and that profitability exceeded plan "driven by one-off special effects and a favorable cost development". Excluding the insurance income, FY2025 EBITDA would be about €478 million, a margin of about 15.5% (derived, illustrative, and not adjusted for one-off integration expenses that worked in the opposite direction).

Balance sheet

Sources: CR2023, CR2024, CR2025. FY2022–FY2023 equity ratios and FY2024 current liabilities are derived. ALTANA's "net financial assets" is its own definition: cash, short-term financial assets, marketable securities and loans granted, less financial liabilities and pension provisions. The short/long-term split of gross financial debt is not stated in the Corporate Report; CR2025 discloses a €100.0 million reclassification of bank liabilities from non-current to current and repayments of €45.0 million, of which €40.0 million was early repayment of a promissory note loan. Goodwill is not separated from other intangibles in the condensed report.

Commentary. The balance sheet is conservative. The Von Roll and Silberline acquisitions moved the group briefly into net debt of €51.8 million at end-2023, and it returned to net financial assets of €207.0 million within two years while paying a dividend. The equity ratio has stayed between 68% and 75%. Net working capital range was unchanged at 135 days in FY2025, missing the forecast of a slight reduction, and working capital intensity (28% of sales) remains the main lever on capital efficiency.

Cash flow

Sources: CR2025 (capex chart 2021–2025, key figures, balance sheet commentary). Free cash flow is derived and excludes acquisitions and divestment proceeds. Buybacks are not applicable for a wholly owned company.

Commentary. Cash conversion is strong: operating cash flow was 77% of EBITDA in FY2025 and 90% in FY2024. Capex has been held within the 5–6% target corridor except in FY2022. In FY2025, 71% of capex went to Europe (54% in FY2024), reflecting the BYK capacity and laboratory build-out in Wesel, Germany and the Netherlands.

Ratios

ROCE and AVA are company-reported (CR2025; cost of capital 7.5%). All other ratios are derived. Net debt/EBITDA is not meaningful because the group is in a net cash position on its own definition for FY2022, FY2024 and FY2025; in FY2023 net debt was 0.13x EBITDA (derived). Interest coverage, ROIC on a standard definition and the cash conversion cycle components (payables days) cannot be computed from the condensed statements and are recorded as not publicly disclosed in the sources reviewed.

Commentary. Returns are positive but thin relative to the quality of the franchises. ROCE of 8.3% sits only modestly above the 7.5% cost of capital, leaving AVA of €22.7 million. The acquired goodwill and intangibles from Von Roll and Silberline, a 135-day working capital range and below-target margins all weigh on capital returns.

Management guidance for FY2026 (PR FY2025, confirmed in PR H1 2026). Operating sales growth in the mid-single-digit percentage range, adjusted for currency and acquisitions, driven mainly by volume. EBITDA was guided in March as roughly at the prior-year level and restated in August as at least on par with the strong prior-year figure. Management warns that geopolitical uncertainty and armed conflicts are expected to weigh significantly on demand and raw-material costs in the second half.

H1 2025 EBITDA is derived from the stated margin and growth rate; H1 2025 headcount is derived from "approximately 290 fewer". H1 2026 operating growth by division: BYK +9%, ECKART +11%, ELANTAS +4%, ACTEGA +10%.

Implied second half. If FY2026 EBITDA merely matches FY2025's €523.0 million, H2 2026 EBITDA would be about €191 million against about €232 million in H2 2025 (derived), a decline of roughly 18%. Either guidance is conservative or management expects a sharp reversal of first-half pre-buying.

Consensus. None exists.

Bull case

1. Margin is back in the target range: 19.8% in H1 2026, with all four divisions growing organically at once for the first time since 2021.

2. ELANTAS has become a structural growth engine at 28% of sales, tied to electrification and data centres, with integration of Von Roll nearly complete.

3. Net cash of €207.0 million, a €300 million EIB line and a patient owner give capacity for value-adding bolt-ons and counter-cyclical investment.

Bear case

1. The H1 2026 strength is partly borrowed: the CEO states customers stocked beyond normal levels, echoing the 2022 build that preceded the 2023 destock (sales -9%, EBITDA -15%).

2. FY2025 earnings were flattered by €45.4 million of insurance income; underlying margin was nearer 15.5%, and organic growth was only 1%.

3. Returns barely exceed the cost of capital (ROCE 8.3% against 7.5%) and Europe, still the largest region and the main capex destination, is structurally weak.

Catalysts and monitorables (next 12 months)

Analyst verdict. ALTANA is a high-quality, conservatively financed specialty chemicals group whose reported numbers currently look better than its underlying trend, and whose underlying trend is nonetheless improving. The franchises are sound: four niche leaders, R&D at 7% of sales, a decentralized laboratory network and a balance sheet that absorbed the second-largest acquisition in its history and returned to net cash within two years. Ownership by SKion removes quarterly pressure and explains the steady capex and R&D through the 2023 downturn.

The central issue is profitability. The group has missed its own 18–20% EBITDA margin corridor for four years, and FY2025's 17.0% included a material insurance gain. The first half of 2026 finally printed 19.8%, but management itself attributes part of the demand to precautionary customer stocking, and its unchanged full-year EBITDA guidance implies a markedly weaker second half. The 2022–2023 sequence is the relevant precedent.

Three things would change the assessment for the better: a full-year 2026 margin inside the corridor without one-offs; sustained mid-single-digit organic growth outside ELANTAS; and a reduction in the 135-day working capital range that lifts ROCE clear of the 7.5% cost of capital. Portfolio momentum is constructive, with ELANTAS now 28% of sales and well placed in electrification, India and the United States growing at double-digit rates, and a coherent build-out of BYK's instruments platform.

Disclosure is the main limitation for outside analysis. Divisional profitability, debt maturities, executive pay and market shares were not available in the documents reviewed, and there is no market price to test conclusions against. On the evidence available, ALTANA is a resilient compounder with a credible but not yet proven margin recovery, and limited financial risk.

No layoffs, guidance cuts, material litigation or regulatory actions were identified in the period.